We are live on
!
Find out more
VOYA Investment Management Portfolio holdings
AUM
$116B
1-Year Est. Return
61.47%
This Fund
S&P 500
This Quarter
Est. Return
-3%
1 Year Est. Return
+61.47%
3 Year Est. Return
+172.42%
5 Year Est. Return
+231.94%
10 Year Est. Return
+892.64%
AUM
$89.9B
AUM Growth
-$6.36B
(-6.6%)
Cap. Flow
-$11.2B
Cap. Flow
% of AUM
-12.46%
Top 10 Holdings %
Top 10 Hldgs %
22.92%
Holding
2,763
New
35
Increased
1,080
Reduced
1,391
Closed
126
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$361M |
| 2 |
Oracle
ORCL
|
+$262M |
| 3 |
MCHPP
Microchip Technology Inc 7.50% Series A Preferred Stock
MCHPP
|
+$253M |
| 4 |
KKR.PRD
KKR & Co 6.25% Series D Preferred Stock
KKR.PRD
|
+$233M |
| 5 |
McKesson
MCK
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$678M |
| 2 |
Amazon
AMZN
|
+$388M |
| 3 |
Datadog
DDOG
|
+$340M |
| 4 |
ServiceNow
NOW
|
+$337M |
| 5 |
Broadcom
AVGO
|
+$270M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.3% |
| 2 | Financials | 10.33% |
| 3 | Healthcare | 9.6% |
| 4 | Consumer Discretionary | 8.14% |
| 5 | Industrials | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Fate Therapeutics
FATE
$317M
| $23.4K | ﹤0.01% |
29,676
-1,583
| -5% | -$1.94K |
|
2502
Caribou Biosciences
CRBU
$169M
| $23K | ﹤0.01% |
25,165
-1,413
| -5% | -$1.84K |
|
2503
Energy Vault
NRGV
$710M
| $22K | ﹤0.01% |
31,688
-1,468
| -4% | -$2.26K |
|
2504
Pliant Therapeutics
PLRX
$66.3M
| $22K | ﹤0.01% |
16,319
-18,504
| -53% | -$112K |
|
2505
Cardlytics
CDLX
$24.7M
| $21.7K | ﹤0.01% |
1,194
-66
| -5% | -$1.89K |
|
2506
Veru
VERU
$46.7M
| $21.2K | ﹤0.01% |
4,316
+56
| +1% | +$347 |
|
|
VTYX
2507
DELISTED
Ventyx Biosciences
VTYX
| $20.8K | ﹤0.01% |
18,078
-1,130
| -6% | -$1.94K |
|
|
FRGE
2508
DELISTED
Forge Global Holdings
FRGE
| $20.5K | ﹤0.01% |
2,433
-127
| -5% | -$1.47K |
|
2509
Chegg
CHGG
$88.9M
| $20K | ﹤0.01% |
31,305
-1,593
| -5% | -$1.97K |
|
2510
Zura Bio
ZURA
$552M
| $19.9K | ﹤0.01% |
15,439
| – | – |
|
2511
Tango Therapeutics
TNGX
$4.31B
| $19.7K | ﹤0.01% |
14,398
-751
| -5% | -$1.84K |
|
2512
Destination XL Group
DXLG
$33M
| $19.7K | ﹤0.01% |
13,504
-2,262
| -14% | -$5.29K |
|
|
APLT
2513
DELISTED
Applied Therapeutics
APLT
| $19.1K | ﹤0.01% |
39,060
+9,945
| +34% | +$5.86K |
|
|
KG
2514
Kestrel Group
KG
$66.3M
| $19K | ﹤0.01% |
1,667
-99
| -6% | -$1.87K |
|
|
LNAI
2515
Lunai Bioworks
LNAI
$10.7M
| $18.1K | ﹤0.01% |
416
-25
| -6% | -$1.6K |
|
2516
Cabaletta Bio
CABA
$465M
| $18K | ﹤0.01% |
12,981
-1,221
| -9% | -$2.6K |
|
2517
Black Diamond Therapeutics
BDTX
$121M
| $17.9K | ﹤0.01% |
11,518
-808
| -7% | -$1.69K |
|
2518
Lineage Cell Therapeutics
LCTX
$278M
| $17.5K | ﹤0.01% |
38,835
| – | – |
|
|
FLNA
2519
Filana Therapeutics
FLNA
$45.1M
| $17.3K | ﹤0.01% |
11,556
-699
| -6% | -$1.76K |
|
2520
Pyxis Oncology
PYXS
$201M
| $15.6K | ﹤0.01% |
15,897
| – | – |
|
2521
X4 Pharmaceuticals
XFOR
$425M
| $14K | ﹤0.01% |
1,977
+20
| +1% | +$275 |
|
|
NOVA
2522
DELISTED
Sunnova Energy
NOVA
| $13.3K | ﹤0.01% |
35,777
+2,392
| +7% | +$4.6K |
|
2523
Lexicon Pharmaceuticals
LXRX
$1.05B
| $6.42K | ﹤0.01% |
13,922
-24,496
| -64% | -$15.5K |
|
|
MRSN
2524
DELISTED
Mersana Therapeutics
MRSN
| $3.48K | ﹤0.01% |
405
-1,043
| -72% | -$16.1K |
|
2525
LanzaTech
LNZA
$67.1M
| $3.09K | ﹤0.01% |
128
-247
| -66% | -$22.2K |
|
Similar funds
VAM
VOYA Investment Management's Q1 2025 Portfolio in Review
As of Q1 2025, VOYA Investment Management held 2,763 positions worth $89.9B, down 6.6% from $96.3B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
VOYA Investment Management withdrew a net $11.2B in Q1 2025, closing 126 positions and reducing 1,391 holdings. Its most notable exit was Apollo Global Management Series A, an estimated $200M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 33% a quarter earlier, followed by Financials and Healthcare.
Against the trend, VOYA Investment Management opened a new position in Microchip Technology Inc 7.50% Series A Preferred Stock worth $252M.
- VOYA Investment Management's largest Q1 2025 buy was Microchip Technology Inc 7.50% Series A Preferred Stock: 5,000,000 shares worth $252M.
- VOYA Investment Management added most to Apple in Q1 2025, an estimated $361M increase.
- VOYA Investment Management's biggest Q1 2025 reduction was Microsoft, cutting an estimated $678M.
- VOYA Investment Management fully exited Apollo Global Management Series A in Q1 2025, selling an estimated $200M.
- VOYA Investment Management's ten largest holdings make up 23% of its $89.9B portfolio in Q1 2025.
- VOYA Investment Management opened 35 new positions and closed 126 in Q1 2025.
- VOYA Investment Management's portfolio value fell 6.6% quarter-over-quarter to $89.9B.
Based on VOYA Investment Management's 13F filing for Q1 2025, filed 15 May 2025.